Biophytis GAAP EPS of -€9.48

Seeking Alpha10/11 23:31

6-K：海外発行者報告書（決算情報）

SEC06/27 01:48

H.C. WainwrightはBIOPHYTIS SPON ADR EACH REP 4000 ORD(POST SPLIT)(BPTSY.US)のレーティングを強気に据え置き、目標株価を15ドルに据え置いた

H.C. WainwrightのアナリストJoseph Pantginisは$BIOPHYTIS SPON ADR EACH REP 4000 ORD(POST SPLIT)(BPTSY.US)$のレーティングを強気に据え置き、目標株価を15ドルに据え置いた。TipRanksのデータによると、このアナリストの最近1年間の的中率は35.3%、平均リターンは3.5%である。注 TipRanksは、金融

Futuニュース06/21 00:32

Biophytis Announces An Exclusive License Agreement With Blanver For BIO101 (20-hydroxyecdysone) In Latin American, Biophytis Will Be Able To Receive Up To €108M Including An Upfront Payment And Further Additional Milestone Payments

Benzinga06/20 16:58

Biophytis Announces The Design Of Its Phase 2 OBA Clinical Study In Obesity With BIO101 (20-hydroxyecdysone)

Benzinga05/14 15:36

Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga04/26 01:57